ALX Oncology Holdings, Inc. (ALXO)
Stock Price:
$76.88 USD
8.37 (12.22%)
Updated November 30, 3:51 PM EST - Market open
Key Info
| Market Cap |
2.85B |
| Revenue (ttm) |
2.40M |
| Net Income (ttm) |
n/a |
| Shares Out |
37.11M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 30 |
| Last Price |
$76.88 |
| Previous Close |
$68.51 |
| Change ($) |
8.37 |
| Change (%) |
12.22% |
| Day's Open |
68.80 |
| Day's Range |
67.59 - 78.00 |
| Day's Volume |
106,163 |
| 52-Week Range |
29.36 - 82.28 |
More Stats
| Market Cap |
2.85B |
| Enterprise Value |
2.60B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
37.11M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.13M |
| Short Ratio |
8.88 |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
1,191.16 |
| PB Ratio |
10.09 |
| Revenue |
2.40M |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
253.72M |
| Net Cash / Share |
6.84 |
| Gross Margin |
18.20% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$64.20*
(-16.49% downside)
Low
60.0
Current: $76.88
High
70.0
Target: 64.20
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Gross Profit | -4.36 | -1.88 |
| Operating Income | -23.98 | -15.75 |
| Net Income | -19.24 | -13.73 |
| Shares Outstanding | 20.25 | 18.10 |
| Earnings Per Share | -1.15 | -0.96 |
| Operating Cash Flow | -14.25 | -13.19 |
| Capital Expenditures | -0.35 | -0.65 |
| Free Cash Flow | -14.60 | -13.84 |
| Cash & Equivalents | 9.02 | 8.26 |
| Total Debt | 5.42 | - |
| Net Cash / Debt | 3.60 | 8.26 |
| Assets | 10.68 | 11.16 |
| Liabilities | 10.95 | 2.01 |
| Book Value | -70.64 | -51.78 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ALX Oncology Holdings, Inc. |
| Country |
United States |
| Employees |
17 |
| CEO |
Jaume Pons |
Stock Information
| Ticker Symbol |
ALXO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ALXO |
| IPO Date |
July 17, 2020 |
Description
ALX Oncology Holdings, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.